Eight in 10 Infants Received RSV Protection in the 2023 to 2024 Season

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 9, 2025.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Jan. 8, 2025 -- Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published online Jan. 8 in JAMA Network Open.

Karen B. Jacobson, M.D., M.P.H., from Kaiser Permanente Northern California in Oakland, and colleagues investigated uptake of RSVpreF among pregnant women at 32 to 36 weeks of gestation and nirsevimab among infants aged younger than 8 months, as well as sociodemographic factors associated with uptake within the early period of availability. The analysis included electronic medical record data among 17,251 infants born to mothers aged 15 to 49 years in a single health system between Oct. 17, 2023 (when nirsevimab became available; RSVpreF became available October 25), and March 31, 2024.

The researchers found that 33.9 percent of infants were exposed to only the maternal RSVpreF vaccine, at a median gestational age of 34.0 weeks, while 40.9 percent of infants received only nirsevimab (median age, 4 days). Only 2.7 percent of infants were exposed to both maternal RSVpreF and nirsevimab, and of these, 31.1 percent were born preterm and 24.1 percent were admitted to the neonatal intensive care unit. Infants of mothers younger than 25 years were less likely than infants of mothers 35 years and older to receive only RSVpreF (26.4 versus 37.9 percent), but thy were more likely to receive only nirsevimab (44.2 versus 40.1 percent). Infants of Asian mothers had the highest exposure to RSVpreF and/or nirsevimab (86.7 percent), while infants of Black mothers had the lowest exposure (70.2 percent).

"The availability of two different RSV protection methods in sufficient supply may have contributed to an increased proportion of infants protected against RSV, which may help mitigate disparities," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Pfizer, which manufactures the RSVpreF vaccine, and Sanofi, which manufactures nirsevimab.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-09 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords